Literature DB >> 6097762

Alteration of viral respiratory infections of mice by prior infection with mouse hepatitis virus.

V A Carrano, S W Barthold, D S Beck, A L Smith.   

Abstract

Pre-infection with mouse hepatitis virus (MHV) strains S, 3, or JHM reduced the ability of mice to seroconvert to PVM. Geometric mean antibody titers to PVM among MHV pre-infected mice were lower than those for control mice given only PVM, and dually infected mice seroconverted to PVM later than mice given PVM alone. PVM was not recovered from normally permissive respiratory tract tissues of MHV-S pre-infected mice. Pre-infection of DBA/2 mice with MHV-S compromised the susceptibility of these mice to lethal Sendai virus infection but did not substantially reduce the titers of infectious Sendai virus recovered from the lungs. Serologic responses to Sendai virus and lung Sendai virus titers were similar in Sendai virus-resistant C57BL/6 mice pre-infected or not with MHV-S.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097762

Source DB:  PubMed          Journal:  Lab Anim Sci        ISSN: 0023-6764


  4 in total

1.  Prevalence of viral antibodies and helminths in field populations of house mice (Mus domesticus) in southeastern Australia.

Authors:  G R Singleton; A L Smith; G R Shellam; N Fitzgerald; W J Müller
Journal:  Epidemiol Infect       Date:  1993-04       Impact factor: 2.451

Review 2.  Potential detrimental effects of rodent viral infections on long-term experiments.

Authors:  G Lussier
Journal:  Vet Res Commun       Date:  1988       Impact factor: 2.459

3.  Modulation of resistance to Salmonella typhimurium infection in mice by mouse hepatitis virus (MHV).

Authors:  M T Fallon; T R Schoeb; W H Benjamin; J R Lindsey; D E Briles
Journal:  Microb Pathog       Date:  1989-02       Impact factor: 3.738

4.  The role of gamma interferon in infection of susceptible mice with murine coronavirus, MHV-JHM.

Authors:  A L Smith; S W Barthold; M S de Souza; K Bottomly
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.